Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
– Trial met primary endpoint of reduction in circulating levels of creatine kinase (CK), a biomarker associated with skeletal muscle damage, in the largest Becker interventional trial to date – –...
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided information regarding the company’s relationship with Dr. Han Phan at Rare Disease...
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Piper Sandler 36th Annual Healthcare...
– On track to announce top-line results from Phase 2 CANYON trial of sevasemten in adults with Becker in December 2024 – – Advanced Phase 2 LYNX and FOX trials of sevasemten in children and...
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 29th International Annual Congress of the World Muscle...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.66 | -2.17678100264 | 30.32 | 32.61 | 28.68 | 667844 | 30.18503023 | CS |
4 | -2.94 | -9.01840490798 | 32.6 | 35.5 | 27 | 926517 | 30.98375402 | CS |
12 | 2.81 | 10.4655493482 | 26.85 | 38.12 | 26.795 | 846019 | 32.33663137 | CS |
26 | 12.18 | 69.6796338673 | 17.48 | 38.12 | 15.0473 | 1023733 | 25.68752467 | CS |
52 | 19.16 | 182.476190476 | 10.5 | 38.12 | 9 | 935661 | 21.31805327 | CS |
156 | 13.58 | 84.4527363184 | 16.08 | 38.12 | 5.12 | 482040 | 17.20602054 | CS |
260 | 2.66 | 9.85185185185 | 27 | 40.49 | 5.12 | 422427 | 17.6520116 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales